132 related articles for article (PubMed ID: 11872085)
1. 'The Mexican approach' to conduct NST.
Ruiz-Argüelles GJ
Eur J Haematol; 2001; 67(5-6):335. PubMed ID: 11872085
[No Abstract] [Full Text] [Related]
2. [Bone marrow transplantation in the treatment of autoimmune disease].
Farge D
Rev Med Interne; 2007 Dec; 28 Suppl 4():S285-7. PubMed ID: 17980463
[No Abstract] [Full Text] [Related]
3. Unrelated bone marrow transplantation using a reduced intensity-conditioning regimen in leukocyte adhesion deficiency.
Takahashi D; Nagatoshi Y; Saito Y; Inagaki J; Nagayama J; Shinkoda Y; Fujita K; Okamura J
Bone Marrow Transplant; 2006 Apr; 37(8):807-8. PubMed ID: 16532019
[No Abstract] [Full Text] [Related]
4. [Allogeneic transplantation of stem cells].
Einsele H; Kanz L
Internist (Berl); 1999 Dec; 40(12):1249-56. PubMed ID: 10642911
[No Abstract] [Full Text] [Related]
5. Optimal benefits for hematopoietic stem cell transplantation: a consensus opinion.
Maziarz RT; Farnia S; Martin P; Komanduri KV
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1671-6. PubMed ID: 25020102
[TBL] [Abstract][Full Text] [Related]
6. Irradiated blood components.
Benson K; Elfenbein G
Am J Clin Pathol; 1997 Feb; 107(2):251; author reply 253-4. PubMed ID: 9024077
[No Abstract] [Full Text] [Related]
7. The Mexican approach to conduct nonmyeloablative stem cell transplantation should not be overlooked.
Ruiz-Argüelles GJ; Gómez-Almaguer D
Int J Hematol; 2003 Jun; 77(5):526-7. PubMed ID: 12841394
[No Abstract] [Full Text] [Related]
8. Rapid full engraftment and successful immune reconstitution after allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in Omenn syndrome.
Gozdzik J; Czogala W; Skoczen S; Krasowska-Kwiecien A; Wiecha O; Mordel A; Lesko E; Majka M; Kowalczyk D; Zembala M
Pediatr Transplant; 2009 Sep; 13(6):760-5. PubMed ID: 18992055
[TBL] [Abstract][Full Text] [Related]
9. Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome--single center experience.
Rzepecki P; Sarosiek T; Szczylik C
Jpn J Clin Oncol; 2006 Jan; 36(1):46-9. PubMed ID: 16423840
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical stem cell transplantation-bone marrow vs peripheral blood.
Gulbas Z
Transfus Apher Sci; 2018 Apr; 57(2):168-170. PubMed ID: 29764770
[TBL] [Abstract][Full Text] [Related]
11. Full chimerism in nonmyeloablative stem cell transplantation in a beta-thalassemia major patient (class 3 Lucarelli).
Hongeng S; Chuansumrit A; Hathirat P; Rerkamnuaychoke B; Chaisiripoomkere W; Jootar S
Bone Marrow Transplant; 2002 Sep; 30(6):409-10. PubMed ID: 12235528
[TBL] [Abstract][Full Text] [Related]
12. Thirty Years of Bone Marrow Transplantation in the Singapore General Hospital.
Phipps C; Ho AY; Linn YC; Gopalakrishnan S; Ang AL; Lee JJ; Ng HY; Lim FW; Goh PS; Loh YS; Tan PH; Koh LP; Koh MB; Lee LH; Goh YT; Ong YW; Hwang WY
Ann Acad Med Singap; 2016 Jul; 45(7):315-7. PubMed ID: 27523512
[No Abstract] [Full Text] [Related]
13. Role and cost efficacy of unrelated cord blood in adult hematopoietic stem transplantation.
Cesaro S
Bone Marrow Transplant; 2005 Aug; 36(3):275. PubMed ID: 15968283
[No Abstract] [Full Text] [Related]
14. Caregivers' quality of life after blood and marrow transplantation: a qualitative study.
Jim HS; Quinn GP; Barata A; Cases M; Cessna J; Gonzalez B; Gonzalez L; Koskan A; Montiel-Ishino F; Pidala J
Bone Marrow Transplant; 2014 Sep; 49(9):1234-6. PubMed ID: 24887387
[No Abstract] [Full Text] [Related]
15. Goals for Pay for Performance in Hematopoietic Cell Transplantation: A Primer.
LeMaistre CF; Farnia SH
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1367-72. PubMed ID: 25889042
[TBL] [Abstract][Full Text] [Related]
16. Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.
Guièze R; Damaj G; Pereira B; Robin M; Chevallier P; Michallet M; Vigouroux S; Beguin Y; Blaise D; El Cheikh J; Roos-Weil D; Thiebaut A; Rohrlich PS; Huynh A; Cornillon J; Contentin N; Suarez F; Lioure B; Mohty M; Maillard N; Clement L; François S; Guillerm G; Yakoub-Agha I
Biol Blood Marrow Transplant; 2016 Feb; 22(2):240-247. PubMed ID: 26256942
[TBL] [Abstract][Full Text] [Related]
17. Recommendations from the European Society for Blood and Marrow Transplantation (EBMT) for a curriculum in hematopoietic cell transplantation.
Mohty M; Duarte RF; Kuball J; Bader P; Basak GW; Bonini C; Carreras E; Chabannon C; Dufour C; Gennery A; Lankester A; Lanza F; Ljungman P; Montoto S; Nagler A; Snowden JA; Styczynski J; Sureda A; Kröger N
Bone Marrow Transplant; 2018 Dec; 53(12):1548-1552. PubMed ID: 29720705
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin and T cell costimulatory blockade as post-transplant treatment promote fully MHC-mismatched allogeneic bone marrow engraftment under irradiation-free conditioning therapy.
Wu T; Sozen H; Luo B; Heuss N; Kalscheuer H; Lan P; Sutherland DE; Hering BJ; Guo Z
Bone Marrow Transplant; 2002 Jun; 29(12):949-56. PubMed ID: 12098061
[TBL] [Abstract][Full Text] [Related]
19. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
[TBL] [Abstract][Full Text] [Related]
20. An unconditioned bone marrow transplantation in a child with purine nucleoside phosphorylase deficiency and its unique complication.
Aytekin C; Yuksek M; Dogu F; Yagmurlu A; Yildiran A; Fitoz S; Kologlu M; Babacan E; Hershfield MS; Ikinciogullari A
Pediatr Transplant; 2008 Jun; 12(4):479-82. PubMed ID: 18208442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
